Original Article

You have full text access to this OnlineOpen article

Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma

A retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group

  1. Andrew Wirth M.B.B.S.1,†,*,
  2. Kally Yuen M.Sc.2,
  3. Michael Barton M.B.B.S.3,
  4. Daniel Roos M.B.B.S.4,
  5. Kumar Gogna M.B.B.S.5,
  6. Gary Pratt M.B.B.S.6,
  7. Craig MacLeod M.B.B.S.7,
  8. Sean Bydder M.B.B.S.8,
  9. Graeme Morgan M.B.B.S.9,
  10. David Christie M.B.B.S.10

Article first published online: 10 AUG 2005

DOI: 10.1002/cncr.21303

Issue

Cancer

Cancer

Volume 104, Issue 6, pages 1221–1229, 15 September 2005

Additional Information

How to Cite

Wirth, A., Yuen, K., Barton, M., Roos, D., Gogna, K., Pratt, G., MacLeod, C., Bydder, S., Morgan, G. and Christie, D. (2005), Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma. Cancer, 104: 1221–1229. doi: 10.1002/cncr.21303

Author Information

  1. 1

    Division of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia

  2. 2

    Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia

  3. 3

    Collaboration for Cancer Outcomes Research and Evaluation, Liverpool Health Service, Liverpool, New South Wales, Australia

  4. 4

    Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia

  5. 5

    Department of Radiation Oncology, Newcastle Mater Misericordiae Hospital, South Brisbane, Queensland, Australia

  6. 6

    Department of Radiation Oncology, Royal Brisbane Hospital, Brisbane, Queensland, Australia

  7. 7

    Department of Radiation Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia

  8. 8

    Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia

  9. 9

    St. Vincent's Radiation Oncology, Sydney, New South Wales, Australia

  10. 10

    Department of Radiation Oncology, East Coast Cancer Centre, Nambour, Queensland, Australia

  1. †

    Fax: (011) 613 96561424

*Division of Radiation Oncology, Peter MacCallum Cancer Centre, St. Andrew's Place, East Melbourne, Victoria, 3002 Australia

Publication History

  1. Issue published online: 31 AUG 2005
  2. Article first published online: 10 AUG 2005
  3. Manuscript Accepted: 25 MAR 2005
  4. Manuscript Revised: 11 MAR 2005
  5. Manuscript Received: 12 JAN 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (153K)

REFERENCES

  • 1
    Jaffe ES. World Health Organisation classification of tumours—pathology and genetics of tumours of the haemopoietic and lymphoid tissues. Lyons, France: IARC Press, 2004.
  • 2
    Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol. 1999; 17: 776–783.
  • 3
    Schwartz R. Hodgkin's disease—time for a change. N Engl J Med. 1997; 337: 494–496.
  • 4
    Marafioti T, Hummel M, Anagnostopoulos I, et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med. 1997; 337: 453–458.
  • 5
    Ohno T, Stribley JA, Wu G, et al. Clonality in nodular lymphocyte-predominant Hodgkin's disease. N Engl J Med. 1997; 337: 459–466.
  • 6
    Russell KJ, Hoppe RT, Colby TV, et al. Lymphocyte predominant Hodgkin's disease: clinical presentation and results of treatment. Radiother Oncol. 1984; 1: 197–205.
  • 7
    Yahalom J. Changing role and decreasing size: current trends in radiotherapy for Hodgkin's disease. Curr Oncol Rep. 2002; 4: 415–423.
  • 8
    Orlandi E, Lazzarino M, Brusamolino E, et al. Nodular lymphocyte predominance Hodgkin's disease: long-term observation reveals a continuous pattern of recurrence. Leuk Lymphoma. 1997; 26: 359–368.
  • 9
    Regula DP Jr., Hoppe RT, Weiss LM. Nodular and diffuse types of lymphocyte predominance Hodgkin's disease. N Engl J Med. 1988; 318: 214–219.
  • 10
    Mauch PM, Kalish LA, Marcus KC, et al. Long-term survival in Hodgkin's disease. Cancer J Sci Am. 1995; 1: 33–42.
  • 11
    Pellegrino B, Terrier-Lacombe MJ, Oberlin O, et al. Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection—a study of the French Society of Pediatric Oncology. J Clin Oncol. 2003; 21: 2948–2952.
  • 12
    Wilder RB, Schlembach PJ, Jones D, et al. European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer. 2002; 94: 1731–1738.
    Direct Link:
  • 13
    Borg-Grech A, Radford JA, Crowther D, et al. A comparative study of the nodular and diffuse variants of lymphocyte-predominant Hodgkin's disease. J Clin Oncol. 1989; 7: 1303–1309.
  • 14
    Pappa VI, Norton AJ, Gupta RK, et al. Nodular type of lymphocyte predominant Hodgkin's disease. A clinical study of 50 cases. Ann Oncol. 1995; 6: 559–565.
  • 15
    Ha CS, Kavadi V, Dimopoulos MA, et al. Hodgkin's disease with lymphocyte predominance: long-term results based on current histopathologic criteria. Int J Radiat Oncol Biol Phys. 1999; 43: 329–334.
  • 16
    Bodis S, Kraus MD, Pinkus G, et. al. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. J Clin Oncol. 1997; 15: 3060–3066.
  • 17
    Wirth A, Chao M, Corry J, et al. Mantle irradiation alone for clinical Stage I–II Hodgkin's disease: long term follow-up and analysis of prognostic factors in 261 patients. J Clin Oncol. 1999; 17: 230–240.
  • 18
    Crennan E, D'Costa I, Liew KH, et al. Lymphocyte predominant Hodgkin's disease: a clinicopathologic comparative study of histologic and immunophenotypic subtypes. Int J Radiat Oncol Biol Phys. 1995; 31: 333–337.
  • 19
    Barton M, Boyages J, Crennan E, et al. Radiotherapy for early infradiaphragmatic Hodgkin's disease: the Australasian experience. Radiother Oncol. 1996; 39: 1–7.
  • 20
    Barton M, Boyages J, Crennan E, et al. Radiation therapy for early stage Hodgkin's disease: Australasian patterns of care. Australasian Radiation Oncology Lymphoma Group. Int J Radiat Oncol Biol Phys. 1995; 31: 227–236.
  • 21
    Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989; 7: 1630–1636.
  • 22
    MathSoft, Inc. S-PLUS 2000 [release 3]. Seattle: MathSoft Inc., 1999.
  • 23
    SPSS Inc. SPSS for Windows [release 11.0.1]. Chicago: SPSS, Inc., 2001.
  • 24
    Kalbfleisch JD. The statistical analysis of failure time data. Ann Oncol. 1980; 7: S109–S113.
  • 25
    Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996; 17: 343–346.
  • 26
    Schlembach PJ, Wilder RB, Jones D, et al. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. Cancer J. 2002; 8: 377–383.
  • 27
    MacManus MP, Hoppe RT. Is radiotherapy curative for Stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996; 14: 1282–1290.
  • 28
    Denham JW, Denham E, Dear KB, et al. The follicular non-Hodgkin's lymphomas—I. The possibility of cure. Eur J Cancer. 1996; 32A: 470–479.
  • 29
    Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a Phase 2 trial. Blood. 2003; 101: 4285–4289.
  • 30
    Rehwald U, Schulz H, Reiser M, et al. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a Phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood. 2003; 101: 420–424.
View Full Article (HTML) Get PDF (153K)